JP2021529208A5 - - Google Patents

Info

Publication number
JP2021529208A5
JP2021529208A5 JP2021500148A JP2021500148A JP2021529208A5 JP 2021529208 A5 JP2021529208 A5 JP 2021529208A5 JP 2021500148 A JP2021500148 A JP 2021500148A JP 2021500148 A JP2021500148 A JP 2021500148A JP 2021529208 A5 JP2021529208 A5 JP 2021529208A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
cells
activates
tslp
Prior art date
Application number
JP2021500148A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595564B2 (ja
JPWO2020010108A5 (https=
JP2021529208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040343 external-priority patent/WO2020010108A1/en
Publication of JP2021529208A publication Critical patent/JP2021529208A/ja
Publication of JPWO2020010108A5 publication Critical patent/JPWO2020010108A5/ja
Publication of JP2021529208A5 publication Critical patent/JP2021529208A5/ja
Application granted granted Critical
Publication of JP7595564B2 publication Critical patent/JP7595564B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500148A 2018-07-05 2019-07-02 がんを処置するための医薬剤を局所送達するための組成物および方法 Active JP7595564B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694100P 2018-07-05 2018-07-05
US62/694,100 2018-07-05
US201862740514P 2018-10-03 2018-10-03
US62/740,514 2018-10-03
PCT/US2019/040343 WO2020010108A1 (en) 2018-07-05 2019-07-02 Compositions and methods for local delivery of pharmaceutical agents to treat cancer

Publications (4)

Publication Number Publication Date
JP2021529208A JP2021529208A (ja) 2021-10-28
JPWO2020010108A5 JPWO2020010108A5 (https=) 2022-07-11
JP2021529208A5 true JP2021529208A5 (https=) 2022-07-11
JP7595564B2 JP7595564B2 (ja) 2024-12-06

Family

ID=69059932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500148A Active JP7595564B2 (ja) 2018-07-05 2019-07-02 がんを処置するための医薬剤を局所送達するための組成物および方法

Country Status (5)

Country Link
US (2) US20210177831A1 (https=)
EP (1) EP3817774A4 (https=)
JP (1) JP7595564B2 (https=)
CN (1) CN112654368B (https=)
WO (1) WO2020010108A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
WO2021206158A1 (ja) * 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2022020655A1 (en) * 2020-07-23 2022-01-27 The Regents Of The University Of Colorado, A Body Corporate Method for treating melanoma
CN116024175A (zh) * 2021-10-27 2023-04-28 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280690C1 (en) * 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
WO2012061630A2 (en) * 2010-11-04 2012-05-10 442 Ventures, Llc Composition and method for treating skin conditions
WO2015070031A1 (en) * 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Similar Documents

Publication Publication Date Title
JP2021529208A5 (https=)
Calvet et al. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
JP2018109022A5 (https=)
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
JP2018502120A5 (https=)
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
JP2015528491A5 (https=)
MX386896B (es) Composiciones y el uso de las mismas para incrementar la inmunidad terapéutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
HRP20200076T1 (hr) Kombinacijsko liječenje raka
JP2016530233A5 (https=)
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
WO2015154059A3 (en) Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
AR104361A1 (es) Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada
JP2018522028A5 (https=)
RU2017146346A (ru) Комбинированная терапия pac-1
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
RU2017134693A (ru) Лекарственное средство
Fleischmann et al. Radioimmunotherapy: future prospects from the perspective of brachytherapy
JPWO2020010108A5 (https=)